In this study, 30 AIDS patients without Mycobacterium avium infection were randomized to receive treatment with azithromycin (1200 mg), granulocyte-monocyte colony-stimulating factor (GM-CSF; 250 mg/m 2 /day for 5 days), or both agents. The M. avium killing capacity of neutrophils and monocytes harvested from each patient before intervention and during (day 4), and after therapy (day 8) was assessed. The mean virus load change in the groups receiving GM-CSF was +0.14 log human immunodeficiency virus RNA. After GM-CSF therapy, neither neutrophils nor monocytes could significantly reduce M. avium growth ( and .31, respectively). Bone pain, myalgia, presyncope, or fever occurred in 55% of P ϭ .96 patients receiving GM-CSF. Thus, the GM-CSF regimen used in this study did not affect virus load, frequently caused adverse reactions, and did not improve the M. avium killing capacity of neutrophils and monocytes. Future studies using a different GM-CSF regimen are indicated.
activity of monocytes as well as neutrophils [1, [8] [9] [10] [11] [12] [13] . We conducted this study in patients with advanced AIDS who were treated with GM-CSF, azithromycin, or both to evaluate the safety of GM-CSF, its impact on plasma virus load, and the ability of monocytes and neutrophils from treated patients to inhibit the growth of M. avium.
Materials and Methods

Eligibility criteria.
Human immunodeficiency virus (HIV)-infected patients у18 years of age with a CD4 cell count р100/ mm 3 measured within 2 months of the study were eligible. Patients were excluded if any of the following were present: absolute neutrophil count (ANC) !500/mm 3 , history of M. avium or Mycobacterium tuberculosis infection, or isolation of M. avium from an isolator blood culture sample obtained 2 weeks before study initiation. Patients were also excluded if they were receiving prednisone (110 mg/day), fluconazole, clarithromycin, ethambutol, isoniazid, rifampin, pyrazinamide, azithromycin, or ciprofloxacin.
Study procedures. A medical history was taken, a physical examination was done, and the following blood tests were performed on day 14 before study initiation: isolator culture for M. avium (Wampole Laboratories, Cranburry, CT), CD4 cell count, complete blood cell count, ANC, absolute monocyte count (AMC), and hepatic transaminase tests. HIV virus load (bDNA assay; Chiron, Emeryville, CA) was measured on days 1 and 7.
The 30 eligible patients were randomized into 1 of 3 treatment groups (10 patients/group) on day 1 for administration of the following therapy: azithromycin (Zithromax; Pfizer, New York City), 1200 mg orally on day 1; GM-CSF (sargramostim [r-met Hu GM-CSF]; Immunex, Seattle), 250 mg/m 2 per day subcutaneously for 5 consecutive days (days 1-5); or both agents. GM-CSF could be reduced to 200 mg/m 2 per day if grade-2 back pain occurred or if the white blood cell count (WBC) was 135,000/mm 3 . Growth of M. avium. Virulent stocks of M. avium were maintained as previously described [7] . The organisms were cultured for 14 days in Middlebrook 7H9 broth (Difco, Detroit) made with endotoxin-free water (Baxter Healthcare, Glendale, CA) containing ADC (albumin, dextrose, catalase; Difco); harvested, centrifuged, and washed twice in Hanks' balanced salt solution; resuspended in fresh Middlebrook 7H9 and H9 broth; and aliquoted and frozen at Ϫ70ЊC. An aliquot was thawed and plated in Middlebrook 7H11 agar OADC (oleic acid, albumin, dextrose, catalase; Difco) to enumerate the number of organisms per milliliter of media.
Infection of neutrophils and monocytes with M. avium and monitoring of bacterial growth. Neutrophils and monocytes were harvested from patients on days 1 (immediately before therapy), 4, and 8, and viability was determined as previously described [6, 7] . Immediately after isolation from peripheral blood, neutrophils and monocytes were plated in separate wells ( cells/well) of a 6 1 ϫ 10 24-well plate and inoculated with M. avium at a ratio of 1 organism per cell. After incubation for 24 h, the cells were harvested and lysed by the addition of 0.2% SDS to release M. avium from the cells. The lysate (100 mL) was incubated in Bactec 12B vials (Becton Dickinson Diagnostic, Sparks, MD) and monitored by the Bactec 460TB system for growth of the organisms as previously described [6, 7] . The vials were read every 12 h until a growth index (GI) of 999, the maximum GI, had been reached. In each assay performed in this study, the GI of M. avium was recorded as log e following a standardized incubation time of 48 h. Data on 14 patients were available for analysis.
Percent reduction of M. avium growth during and after therapy. The relative growth of M. avium for neutrophils and monocytes is the GI of M. avium within GI of M. avium in broth cells Ϭ the alone. For each patient, the ratio of M. avium growth after therapy was determined by dividing the relative growth after therapy by the relative growth before the drug was administered. Thus, each patient served as his or her own control (day 1 immediately before therapy) to determine the influence of therapy on the ability of neutrophils and monocytes to inhibit M. avium growth. Wilcoxon's rank test was used to assess differences among groups on each pair of days. For a subset of patients, Friedman's x 2 test was used to look at differences by day for groups 2 and 3 combined. P ! .05 was considered significant.
Results
The clinical characteristics of the AIDS patient population (mean CD4 cell count, 39 cells/mm 3 ; mean baseline virus load, 3.7 log HIV RNA; mean baseline ANC, 2100/mm 3 ; and mean baseline AMC, 400/mm 3 ) are outlined in table 1. Eighteen patients had an AIDS-defining illness that was diagnosed a mean of months before the study. Of the 18 patients, 7 had 11 ‫ע‬ 16 Pneumocystis carinii pneunomia, 3 had esophageal candidiasis, 3 had cytomegalovirus retinitis, 2 had cerebral toxoplasmosis, . The agents used as prophylaxis against P. carinii included trimethoprim sulfamethoxazole (18 patients), dapsone (6 patients), and aerosolized pentamidine (3 patients). There were no significant differences in any of these clinical characteristics between the 3 groups.
The mean virus load change from day 1 to day 7 in the GM-CSF alone and GM-CSF-azithromycin combination groups was ϩ0.14 and Ϫ0.11 log HIV RNA, respectively. There were no significant differences in the changes in HIV virus load before and after therapy between any of the 3 treatment groups.
Adverse reactions due to study medications occurred in several patients. Fifty-five percent of patients receiving GM-CSF alone or in combination with azithromycin experienced adverse reactions, and 60% receiving GM-CSF alone had presyncope (1 patient, who discontinued the study medication), myalgia or bone pain (2 patients), headache (2 patients), or vomiting (1 patient). Fifty percent of patients receiving the GM-CSF-azithromycin combination had chest pain (1 patient, who discontinued the study medications), fever (1 patient), dizziness (1 patient), myalgia or bone pain (1 patient), or nausea (1 patient). A reduction of the GM-CSF dosage to 200 mg/m 2 per day was required in each patient who had myalgia or bone pain and resulted in improvement of symptoms. Twenty percent of patients receiving azithromycin alone experienced nausea and vomiting. There was a statistically significant increase in total WBC ( ) and ANC ( ) but not AMC ( ) P ϭ .01 P ϭ .03 P ϭ .25 on days 1 and 4 between patients who received azithromycin alone and those who received GM-CSF alone or in combination with azithromycin. The increase in these values was transient, as the WBC began to return to the baseline value 2 days after discontinuation of GM-CSF (table 1) . No patient expe-rienced clinical symptoms associated with the maximal elevation in WBC, and no significant increase occurred in levels of transaminase.
Data assessing the relative growth of M. avium before, during, and after treatment were analyzed for 14 patients (figure 1), of whom 4 received azithromycin alone, 5 received GM-CSF alone, and 5 received both. The assays assessing the relative growth of M. avium could not be done for the remaining 16 patients for one of the following reasons: the minimum numbers of neutrophils and monocytes were not isolated from the patient on 11 study day (8 patients), the patient dropped out of the study because of toxicity (2 patients), the control M. avium cultures in broth yielded an insufficient growth on 1 study day (2 patients), or the patient failed to return for the study completion (day 8) follow-up visit (4 patients). For neutrophils and monocytes, there was no reduction in M. avium growth after treatment (day 8) in the groups receiving GM-CSF alone or GM-CSF-azithromycin (neutrophils, ; monocytes, P ϭ .96 ), and there were no significant differences in M. avium P ϭ .31 growth from days 1 and 4 (neutrophils, ; monocytes, P ϭ .49 ) and from days 1 and 8 (neutrophils, ; mono-P ϭ .21 P ϭ .24 cytes, ). P ϭ .59
Discussion
Neutrophils or monocytes harvested from AIDS patients treated with subcutaneous GM-CSF alone (250 mg/m 2 daily for 5 consecutive days) or with azithromycin (1200 mg) did not demonstrate an improved capacity to kill M. avium. Moreover, the dosage of GM-CSF used in this study resulted in frequent adverse reactions, some of which required a dose reduction or disruption of continued GM-CSF therapy. No remarkable change in plasma HIV virus load was noted, a finding that confirms the findings of other studies (i.e., that patients using antiretroviral therapy may receive GM-CSF, a cytokine that potentially could increase HIV expression, without increasing HIV viremia) [14] .
Inadequate serum or intracellular GM-CSF levels might explain for the differences between the results of this study and our previous findings of enhanced growth inhibition of M. avium by neutrophils from AIDS patients when GM-CSF (2000 U/mL) was added exogenously [6] . The minimum effective concentration in our previous report was 2000 mg/mL [6] , and the dose of GM-CSF used in this study (250 mg/m 2 per day) was selected on the basis of safety and tolerability. It is possible that the dose and duration of GM-CSF used in this study did not result in the minimum serum or intracellular levels that would permit enhanced microbicidal activity. Serum levels were not measured in this trial because current methodology cannot distinguish administered GM-CSF from that produced endogenously.
It is possible that a regimen of GM-CSF of more prolonged duration could achieve enhanced cellular mycobacterial microbicidal activity. Increasing the dose of GM-CSF would not be a reasonable strategy option because of the toxicities observed in the present study. Extending the duration of GM-CSF treatment to 28 days and using an incremental regimen with an initial dose that was lower than that used in this study could be considered as a possible design for a regimen to be investigated in future trials. In addition, harvesting neutrophils and monocytes beyond 7-28 days may also be required to demonstrate an enhanced microbicidal effect of GM-CSF. One study investigating GM-CSF for treatment of DMAC in AIDS patients utilized a regimen of this design [8] . In this study, 2 of 5 AIDS patients with DMAC that was treated for 28 days with GM-CSF (initially begun at 50 mg/m 2 per day and increased to 250 mg/m 2 per day) developed side effects attributable to this agent [8] . In this study, patients with adverse reactions were managed by withholding the drug for 1 week, with eventual dose reduction in 1 patient and continuation of full dose in the other patient. Enhanced bactericidal activity was first noted after 28 days of treatment [8] .
Thus, the absence of an enhanced microbicidal activity of neutrophils and monocytes from patients treated with GM-CSF instead of azithromycin does not exclude a potential role for this agent in the prophylaxis against DMAC. Furthermore, GM-CSF given to AIDS patients in the amount used in this study resulted in significant adverse reactions but no notable elevation in HIV RNA. Thus, the design of this study may have failed to demonstrate a possible benefit of GM-CSF. The findings of this study therefore support the need to conduct larger controlled studies to determine the optimal dose and duration of GM-CSF treatment, to demonstrate enhanced neutrophil and monocyte microbicidal activity.
